Summary
- The Health and Social Care Committee has urged ministers to drop Palantir’s Federated Data Platform when a break clause arises in February 2027.
- MPs cite public concern about data security, doubts about the FDP’s efficacy, and the availability of alternatives.
- The row links digital health, public trust, supplier dependency, data governance, and the NHS’s wider analogue-to-digital shift.
Palantir faces renewed political pressure over its role in the NHS Federated Data Platform after MPs urged ministers to use a February 2027 break clause to drop the product and prepare an alternative.
The House of Commons Health and Social Care Committee has written to Health Innovation Minister Preet Kaur Gill after a recent evidence session, citing public concern about data security, doubts about the FDP’s efficacy, and the availability of other solutions. The committee recommends either developing an in-house replacement or seeking an alternative from UK-owned and UK-based providers.
The Federated Data Platform is one of the most sensitive digital programmes in the NHS because it sits at the intersection of patient data, operational planning, service improvement, procurement, and trust. It is intended to help the health service use data to understand patterns, plan services, and support operational decisions. The dispute is not about whether the NHS needs better data infrastructure. It is about who builds it, how it is governed, and whether patients and clinicians trust the arrangement.
The committee says serious mistrust of Palantir could deter patients from sharing medical data with the NHS, undermining the broader shift from analogue to digital health services. That is a practical risk, not just a reputational one. Digital health programmes depend on consent, legitimacy, data quality, and public confidence. If people believe their information is being handled by a supplier they do not trust, the system can lose value before the technology itself is assessed.
The committee also points to uncertainty over performance claims. NHS England had published claims that there was proof of improvements since the FDP was introduced, including waiting list reductions and more procedures carried out. It has since clarified that it cannot say conclusively that the FDP caused those changes because other variables were not controlled for.
That distinction is important for public sector technology procurement. Major platforms are often defended through broad claims about efficiency, productivity, and service outcomes. Yet without robust evaluation, it becomes difficult to separate the effect of the platform from staffing, management changes, funding, local initiatives, or wider operational pressures.
There is also a vendor dependency issue. The committee has warned that some NHS trusts already have capabilities exceeding what the FDP offers, suggesting that alternatives could be scaled. Whether that is operationally realistic before spring 2027 is another matter. Replacing a national data platform would require procurement, transition planning, technical migration, governance, security assurance, user adoption, and contractual risk management.
The risk for ministers is that both options carry costs. Keeping Palantir may preserve continuity and avoid a hurried replacement, but it prolongs a trust problem that has become politically salient. Dropping the FDP could satisfy critics and support a sovereignty argument, but it may create delivery risk if an alternative is not ready, properly funded, and technically credible.
The story also sits inside a broader digital government debate. The UK wants to modernise public services through better data, automation, digital identity, and shared platforms. Yet large technology contracts in sensitive domains repeatedly run into questions over transparency, dependency, accountability, and foreign supplier control. The NHS magnifies those questions because medical data is both personally intimate and operationally valuable.
Technology suppliers should read the committee’s intervention as a warning that public sector platform contracts cannot rely only on technical capability. Trust architecture matters. Open procurement, clear data access rules, evidence of performance, exit planning, and public communication are part of the product in domains where the state handles sensitive citizen data.
The February 2027 break clause now creates a political and operational deadline. Ministers will need to show whether they are preparing a credible alternative, renegotiating governance, or accepting the risks of continuity. The NHS’s wider digital programme will be judged not only by the sophistication of its platforms, but by whether patients, clinicians, and public bodies believe the infrastructure is legitimate enough to use.
